Unexpected delays and cancelling of one of their prime products has set back the time table some but now things are headed in the right direction for sure. There is no doubt their pipeline is going to continue to increase with multiple drug launches this year and most likely the return of Lodrane 24 via ECR as well. They have substantial funding now for phase 3 216 trials also. I can see nothing negative on the horizon for 2012. They will be profitable next quarter easily and for many years after that as well.
News 
Market Data 
Discover 
